[EN] NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE [FR] NOUVEAUX COMPOSÉS HÉTÉROARLYLE HÉTÉROCYCLYLE POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO
申请人:Dow AgroSciences LLC
公开号:US20160024026A1
公开(公告)日:2016-01-28
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the following formula (“Formula One”).
[EN] MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY<br/>[FR] INHIBITEURS DE LA MONOACYLGLYCÉROL LIPASE DE MODULATION DE L'ACTIVITÉ CANNABINOÏDE
申请人:UNIV NORTHEASTERN
公开号:WO2009052319A1
公开(公告)日:2009-04-23
Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.
The direct reductive amination of electron-deficient amines with aldehydes: the unique reactivity of the Re2O7 catalyst
作者:Braja Gopal Das、Prasanta Ghorai
DOI:10.1039/c2cc33185c
日期:——
An unprecedented direct reductive amination of electron-deficient amines such as Cbz-, Boc-, EtOCO-, Fmoc-, Bz-, ArSO2-, Ar2PO-, etc. protected amines with aldehydes is achieved using the Re2O7 catalyst and silanes as the hydride source. Excellent regioselective mono-alkylation and chemoselective reductive-amination were observed.
NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
申请人:F. Hoffmann-La Roche AG
公开号:EP3623369A1
公开(公告)日:2020-03-18
The present invention relates to compounds of formula (I),
wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
[EN] FERROPTOSIS INHIBITORS–DIARYLAMINE PARA-ACETAMIDES<br/>[FR] INHIBITEURS DE FERROPTOSE-DIARYLAMINE PARA-ACÉTAMIDES
申请人:SIRONAX LTD
公开号:WO2021175200A1
公开(公告)日:2021-09-10
Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.